CNTB
No price yet
Announcements
Nothing here yet
Daily updates
- Connect Biopharma reported positive Phase 2 Seabreeze STAT COPD topline data for single-dose rademikibart in acute COPD exacerbations with type 2 inflammation.Sep 30, 2026
- Connect Biopharma reported positive Phase 2 Seabreeze STAT asthma results for rademikibartSep 16, 2026
- Connect Biopharma reported positive Phase 2 Seabreeze STAT asthma results for rademikibartSep 15, 2026
- Rademikibart Phase 2b asthma data were expected in early September 2026Sep 7, 2026
FDA designations
Nothing here yet
News
- Connect Biopharma reports positive preliminary topline results from its global Phase 2 trial of rademikibart as add-on therapy for acute COPD exacerbations in adults with type 2 inflammationSep 30, 2026
- Connect Biopharma reported positive preliminary topline data from its global Phase 2 study of rademikibart as an add-on treatment for acute asthma exacerbations with Type 2 inflammationSep 15, 2026
- Connect Biopharma completed enrollment in the Phase 2 Seabreeze STAT asthma study of rademikibartJun 18, 2026
- Connect Biopharma plans to terminate its ADR program and directly list ordinary shares on NasdaqJul 21, 2025
- Connect Biopharma's exclusive licensee Simcere submits new drug application for Rademikibart to treat atopic dermatitis in ChinaJul 9, 2025